NCT07415226Not yet recruiting
Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes
Effectiveness and Safety of Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes: a Retrospective, Observational Study
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
To assess the real-world impact of glucose-lowering drugs (GLDs) as an adjunct to insulin in Chinese patients with type 1 diabetes (T1DM). Does glucose-lowering drugs (GLDs) as an adjunct to insulin improve clinical outcomes in Chinese patients with type 1 diabetes (T1DM) when used long-term in real-world practice?
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 10 Feb 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Diseases
- Type 1 diabetes
- NCT number
- NCT07415226
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 May 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient had already used hypoglycemic drugs as an adjunct to insulin therapy before admission;
- Patients who have no medication records or have not followed the treatment plan formulated by the doctor.
Other illness
- DKA、 Serious infection, perioperative status, severe trauma, pregnancy, patient's past or current involvement in interventional clinical research；
Other
- The standard for determining stress hyperglycemia by the supervising physician;
Who the study is looking for
- The research group consists of T1DM patients who first used oral hypoglycemic drugs from January 2013 to June 2024 and had a glycated hemoglobin level of \>= 7%; The control group consisted of T1DM patients who maintained only insulin treatment regimen and had glycated hemoglobin \>= 7%;
- Age \>= 18 years old;
- At least one recorded HbA1c value before the start of treatment;
- Maintain medication regimen as needed from baseline to at least 3 months;
- Record the first glycated hemoglobin value after treatment.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.